Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Issues And Trends In Healthcare Delivery System

Issues And Trends In Healthcare Delivery System

The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...

Diabetes: Symptoms, Diagnosis, and Complications

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...

Pathophysiology of Diabetes

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measure.

Journal of managed care & specialty pharmacy·2024

Same author

Impact of continuous glucose monitoring on emergency department visits and all-cause hospitalization rates among Medicaid beneficiaries with type 2 diabetes treated with multiple daily insulin or basal insulin therapy.

Journal of managed care & specialty pharmacy·2024

Same author

Reduction in Healthcare Resource Utilization Following Treatment With a Home-Based Footworn Device in Patients With Knee Osteoarthritis: A Retrospective Claims Analysis.

Journal of health economics and outcomes research·2024

Same author

Profile of a population-based diabetic macular oedema study: the Liverpool Eye and Diabetes Study (Sydney).

BMJ open·2019

Same author

Hypoglycemia and diabetes: an update of current trends and treatment.

Journal of continuing education in nursing·2014

Same author

International Diabetes Federation.

Diabetes research and clinical practice·2013

Search research articles

Related Experiment Video

Updated: Oct 19, 2025

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Published on: March 15, 2024

Insurance Coverage for Emerging Diabetes Technologies: Payers' Perspective.

Tim Nolan¹, Marie Frazzitta²

¹TEN Healthcare Strategies, Newtown, Pennsylvania, USA.

Diabetes Technology & Therapeutics

|September 21, 2021

Summary

Commercial insurers evaluate key factors when deciding on coverage for advanced diabetes management technologies. Understanding these criteria is crucial for clinicians and patients navigating insurance eligibility for tools like continuous glucose monitors.

Keywords:

Continuous glucose monitoring Cost Diabetes Insurance Risk stratification

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Related Experiment Videos

Last Updated: Oct 19, 2025

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Published on: March 15, 2024

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Area of Science:

Endocrinology and Metabolic Diseases
Health Services Research
Medical Technology Assessment

Background:

Technological advancements have introduced innovative diabetes self-management tools, including continuous glucose monitoring (CGM), automated insulin delivery (AID) systems, and smart connected insulin pens.
While the clinical benefits of these emerging diabetes technologies are established, their integration into practice necessitates a thorough cost-benefit analysis for insurers.
Clinicians often lack awareness regarding the decision-making processes employed by commercial insurers for technology coverage.

Purpose of the Study:

To elucidate the key factors commercial insurers consider when determining eligibility criteria for advanced diabetes management technologies.
To bridge the knowledge gap between healthcare providers and insurance companies regarding reimbursement policies for diabetes tech.

Main Methods:

Review of commercial insurer decision-making processes for technology adoption.
Analysis of factors influencing coverage eligibility for diabetes management tools.

Main Results:

Insurers evaluate clinical efficacy, cost-effectiveness, and patient outcomes when assessing new diabetes technologies.
Evidence-based data and formulary guidelines significantly impact coverage decisions.
Understanding payer perspectives is essential for successful technology integration.

Conclusions:

Navigating insurance coverage for advanced diabetes technologies requires a comprehensive understanding of insurer criteria.
Addressing cost and demonstrating value are paramount for securing reimbursement.
Further dialogue between providers, patients, and payers can facilitate access to innovative diabetes care solutions.